Antibody-drug conjugate targeting antigenic epitope polypeptide, and use thereof
By modifying the unique antigen epitope polypeptide on the surface of tumor cells and using specific antibodies to mediate cytotoxic drugs, the toxicity problem of antibody drug conjugates in normal cells is solved, efficient specific killing of tumors is achieved, and treatment is improved index.
Patent Information
- Application Number
- PCT/CN2024/093815
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-28
AI Technical Summary
Antibody drug conjugates have toxicity problems when treating tumors, especially non-targeted normal cells uptake of cytotoxic drugs, resulting in secondary toxicity, how to improve the therapeutic index and reduce exposure to normal cells.
The specific killing of tumors is achieved by modifying specific antigen epitope polypeptides, such as the TT3 sequence, on the surface of tumor cells, and targeting and mediating cytotoxic drugs to kill tumor cells.
It improves the anti-tumor killing effect, reduces the toxicity to normal cells, and significantly improves the therapeutic index of cytotoxic drugs.
Smart Images

Figure PCTCN2024093815-FTAPPB-I100001 
Figure PCTCN2024093815-FTAPPB-I100002 
Figure PCTCN2024093815-FTAPPB-I100003
Abstract
Description
Antibody-drug conjugates targeting antigen epitope peptides and their applications Technical Field
[0001] The present invention relates to the field of medicine, specifically to the field of antibody-drug conjugates, and in particular to antibody-drug conjugates targeting antigen epitope polypeptides and applications thereof. Background Art
[0002] Antibody-drug conjugates (ADCs) are a class of biological drugs that connect a biologically active cytotoxic drug (payload) to an antibody through a chemical linker. In recent years, a number of antibody-drug conjugates have made breakthroughs in tumor treatment, making them a major emerging treatment method after surgery, chemotherapy, and radiotherapy. ADC drugs combine the highly specific targeting ability of antibodies with the efficient killing effect of cytotoxic drugs, and can achieve accurate and efficient clearance of cancer cells. They have become one of the hot spots in the field of cancer research and development. As of March 2023, 16 antibody-drug conjugates have been approved worldwide. Currently, the research field of ADCs is still expanding, and they are mainly used in the study of hematological malignancies and solid tumors.
[0003] Although ADC drugs have been favored by many medical workers and developed rapidly, their toxicity is still a very important challenge faced in clinical practice. For example, the uptake of ADC in non-targeted normal cells will transmit cytotoxicity. For another example, the expression of the antigen targeted by ADC in normal tissues (although the expression level is low) may lead to ADC target-dependent uptake and secondary toxicity. The ideal ADC drug aims to improve the therapeutic index of cytotoxic drugs and reduce exposure in normal cells by more selectively delivering cytotoxic drugs to tumor cells. How to avoid or reduce drug toxicity in the process of ADC drug development is a problem that R&D personnel need to consider during development.
[0004] Summary of the Invention
[0005] The present invention solves at least one of the technical problems mentioned above to a certain extent. Selecting antigens that are low-expressed or not expressed in normal tissues for specific targeting can undoubtedly effectively reduce the toxicity of ADCs. The targets or antigens targeted by ADC drugs that are already on the market or under research are all antigens that are highly expressed in tumor cells and low-expressed in normal cells. Even so, cytotoxicity is still inevitable. The present invention can be used to distinguish tumor cells and / or cancer cells from normal cells by modifying the surface of tumor cells and / or cancer cells with unique amino acid sequences (for example, amino acid sequences (antigenic epitope polypeptides) that are not contained in the amino acid sequences of mammalian cell membrane proteins or secretory proteins in the natural state). Tumor cells and / or cancer cells can then be "targeted" by antibodies that specifically target the modified amino acid sequences on the surface of tumor cells and / or cancer cells. Specific targeting of tumor cells and / or cancer cells can be achieved; the cytotoxic drugs are killed by antibody internalization, thereby achieving specific tumor killing. Taking TT3 as an example, the TT3 sequence contains an antigenic epitope peptide. Comparison with human genomic databases revealed that this epitope peptide is not expressed in the human genome, making it suitable for surface modification on tumor and / or cancer cells. Antibodies targeting TT3 can specifically recognize and bind to TT3, achieving specific targeting of tumor and / or cancer cells. Simultaneously, antibody-mediated cytotoxic drug killing of tumor or cancer cells enhances anti-tumor efficacy.
[0006] Specifically, the present invention provides the following technical solutions:
[0007] In a first aspect of the present invention, a method for preparing an antibody conjugate comprising: providing an antibody or antigen-binding fragment thereof targeting an antigenic epitope polypeptide; wherein, in a natural state, the amino acid sequence of a mammalian cell membrane protein or secretory protein does not contain the amino acid sequence of the antigenic epitope polypeptide; and wherein the antigenic epitope polypeptide is differentially and highly expressed on tumor cells / cancer cells compared to normal human cells. The antibody or antigen-binding fragment specifically binds to the antigenic epitope polypeptide on the tumor cells / cancer cells and exhibits endocytosis with an EC50 of ≤100 nM. For example, the antibody or antigen-binding fragment may exhibit endocytosis with an EC50 of ≤90 nM, EC50 ≤80 nM, EC50 ≤70 nM, EC50 ≤60 nM, EC50 ≤50 nM, EC50 ≤40 nM, EC50 ≤30 nM, EC50 ≤20 nM, EC50 ≤10 nM, EC50 ≤5 nM, EC50 ≤4 nM, EC50 ≤3 nM, EC50 ≤2 nM, or EC50 ≤1 nM.
[0008] In a second aspect, the present invention provides a use of an antibody-drug conjugate in the preparation of a medicament for treating cancer and / or tumors, wherein the antibody-drug conjugate is an antibody or antigen-binding fragment targeting an antigenic epitope polypeptide coupled to one or more therapeutic agents; wherein, in a natural state, the amino acid sequence of a mammalian cell membrane protein or secretory protein does not contain the amino acid sequence of the antigenic epitope polypeptide; compared to normal human cells, the antigenic epitope polypeptide is differentially and highly expressed on tumor cells / cancer cells; the antibody or antigen-binding fragment specifically binds to the antigenic epitope polypeptide on the tumor cells / cancer cells and exhibits endocytosis with an EC50 of ≤100 nM.
[0009] In a third aspect, the present invention provides an antibody-drug conjugate targeting an antigenic epitope polypeptide, comprising an antibody or antigen-binding fragment thereof targeting the antigenic epitope polypeptide conjugated to one or more therapeutic agents; wherein, in a natural state, the amino acid sequence of a mammalian cell membrane protein or secretory protein does not contain the amino acid sequence of the antigenic epitope polypeptide; compared with normal human cells, the antigenic epitope polypeptide is differentially and highly expressed on tumor cells / cancer cells, and the antibody or antigen-binding fragment specifically binds to the antigenic epitope polypeptide on the tumor cells / cancer cells and exhibits endocytosis with an EC50 of ≤100 nM.
[0010] In a fourth aspect, the present invention provides a pharmaceutical composition comprising the antibody-drug conjugate according to the third aspect of the present invention.
[0011] In a fifth aspect, the present invention provides a kit comprising the antibody-drug conjugate according to the third aspect of the present invention.
[0012] The sixth aspect of the present invention provides a method for preventing and / or treating a disease, comprising administering to a subject in need thereof an effective amount of the antibody-drug conjugate of the third aspect, or the pharmaceutical composition of the fourth aspect.
[0013] The seventh aspect of the present invention provides a use of an antibody-drug conjugate in preparing a drug or a kit, wherein the antibody-drug conjugate is the antibody-drug conjugate according to the third aspect.
[0014] The eighth aspect of the present invention provides a use of an antibody or antigen-binding fragment thereof targeting an antigen epitope polypeptide in the preparation of an antibody-drug conjugate;
[0015] Wherein, in a natural state, the amino acid sequence of a mammalian cell membrane protein or secretory protein does not contain the amino acid sequence of the antigenic epitope polypeptide;
[0016] Compared to normal human cells, the antigen epitope polypeptide is differentially and highly expressed on tumor cells / cancer cells, and the antibody or antigen-binding fragment specifically binds to the antigen epitope polypeptide on the tumor cells / cancer cells;
[0017] The amino acid sequence of the antigenic epitope polypeptide has one or more sequences derived from Strep tag I or Strep tag II.
[0018] A ninth aspect of the present invention provides an antibody-drug conjugate targeting an antigen epitope polypeptide, comprising an antibody or antigen-binding fragment thereof targeting an antigen epitope polypeptide conjugated to one or more therapeutic agents;
[0019] Wherein, in a natural state, the amino acid sequence of a mammalian cell membrane protein or secretory protein does not contain the amino acid sequence of the antigenic epitope polypeptide;
[0020] Compared to normal human cells, the antigen epitope polypeptide is differentially and highly expressed on tumor cells / cancer cells, and the antibody or antigen-binding fragment specifically binds to the antigen epitope polypeptide on the tumor cells / cancer cells;
[0021] The amino acid sequence of the antigenic epitope polypeptide has one or more sequences derived from Strep tag I or Strep tag II. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] FIG1 is a diagram showing the ELISA test results of an antibody targeting TT3 and a humanized antibody thereof provided according to an embodiment of the present invention, as well as the FACs test results of HCT116-TT3 cells, SK-HEP-1-TT3 cells, and MC38-TT3 cells.
[0023] FIG2 is a diagram showing the SDS-PAGE results of the antibody-drug conjugate TT3-MMAE provided in Example 2 of the present invention.
[0024] FIG3 is a graph showing the SEC results of the antibody-drug conjugate TT3-MMAE provided in Example 2 of the present invention.
[0025] FIG4 is a UV-Vis result diagram of the antibody drug conjugate TT3-MMAE provided in Example 2 of the present invention.
[0026] FIG5 is a graph showing the cell binding activity results of the antibody-drug conjugate TT3-MMAE provided in Example 3 of the present invention.
[0027] FIG6 is a diagram showing the endocytosis results of the antibody-drug conjugate TT3-MMAE provided in Example 3 of the present invention.
[0028] FIG7 is a graph showing the cell killing results of the antibody-drug conjugate TT3-MMAE provided in Example 3 of the present invention. Specific implementation plan
[0029] The technical solution of the present invention is described in detail below with reference to specific examples. At the same time, in order to facilitate understanding by those skilled in the art, some terms of the present invention are explained and illustrated. It should be noted that these explanations and illustrations are only used to facilitate understanding by those skilled in the art and should not be regarded as limiting the scope of protection of the present invention.
[0030] As used in this specification and claims, "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. The words "tumor," "cancer," "tumor cell," and "cancer cell" have meanings commonly recognized in the art. The term "plurality" includes two.
[0031] The term "effective amount" herein refers to the amount of a drug, formulation, or active ingredient that can exhibit a detectable therapeutic effect, inhibitory effect, or preventive effect. The detectable therapeutic effect, inhibitory effect, or preventive effect mentioned above can be detected by any detection method known in the art.
[0032] As used herein, the term "oncolytic virus" refers to a virus that can selectively replicate in tumor cells and lyse tumor cells.
[0033] As used herein, the term "antibody" is used in the broadest sense to refer to a protein or polypeptide that contains an antigen binding site, antigen binding portion, or antigen binding fragment, encompassing natural antibodies and artificial antibodies of various structures, including but not limited to complete antibody forms or antigen binding fragments of antibodies.
[0034] As used herein, the terms "intact antibody" or "complete antibody" are used synonymously to refer to a protein comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain is composed of a heavy chain variable region (abbreviated as VH) and a heavy chain constant region (also referred to as a heavy chain constant domain, abbreviated as CH). The heavy chain constant region includes the heavy chain constant domain CHI, the heavy chain constant domain C2, and the heavy chain constant domain C3. Each light chain is composed of a light chain variable region (abbreviated as VL) and a light chain constant region (also referred to as a light chain constant domain, abbreviated as CL). VH and VL can be further divided into complementarity determining regions (also referred to as hypervariable regions or hypervariable regions, abbreviated as CDRs or HVRs), interspersed with conserved framework regions (FRs). Each VH and VL comprises three CDRs and four FRs, arranged from the amino terminus (N-terminus) to the carboxyl terminus (C-terminus) in the following sequence: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The CDRs of the heavy chain variable region are referred to as HCDR1, HCDR2, and HCDR3, respectively, starting from the amino terminus, and the CDRs of the light chain variable region are referred to as LCDR1, LCDR2, and LCDR3, respectively, starting from the amino terminus.
[0035] "Antigen-binding fragment," "antigen-binding portion," or "antigen-binding site" refers to a portion of a full-length antibody that exhibits specific binding to an antigen. As mentioned above, the hypervariable or hypervariable regions of the heavy and light chains of an intact antibody exhibit specific binding to an antigen. Examples of antigen-binding fragments or portions include, but are not limited to, Fab, Fab', F(ab')2, bispecific Fab' and Fv fragments, linear antibodies, single-chain antibodies, single-domain antibodies, bispecific antibodies, and multispecific antibodies. Papain digestion of an intact antibody produces two identical antigen-binding fragments, called Fab fragments, each containing the heavy and light chain variable regions and the light chain constant domain and the heavy chain constant domain CH1. Fab' fragments differ from Fab fragments by having a few additional residues at the carboxyl terminus of the heavy chain constant domain CH1, including one or more cysteines from the antibody hinge region. Pepsin digestion of an intact antibody produces F(ab')2 fragments. F(ab')2 fragments have two antigen-binding F(ab) moieties linked by a disulfide bond, and F(ab')2 fragments are bivalent antibodies. A single-chain antibody is a fusion protein composed of the variable region of the heavy chain and the variable region of the light chain of an antibody connected by a flexible short peptide consisting of about 10-25 amino acids. A single-domain antibody is an antibody fragment composed of the variable region of a single monomer. Since single-domain antibodies are usually derived from the variable region of the heavy chain of camel antibodies or shark antibodies, they are often called nanobodies. A "multispecific antibody" (also called a multiantibody) refers to an antigen-binding portion that specifically binds to epitopes of at least two different biological molecules or at least two different epitopes of the same biological molecule. For example, a "multispecific antibody can be a bispecific antibody (also called a bispecific antibody), or a trispecific antibody, etc. "Multi" means two or more.
[0036] When the term "and / or" or " / " is used to connect two or more optional items, it should be understood to mean any one of the optional items or any two or more of the optional items.
[0037] The term "comprising" or "including" means including the elements or steps mentioned, but does not exclude other elements or steps. Of course, unless otherwise specified, "comprising" or "including" also covers the situation where it consists of the elements or steps mentioned. For example, when referring to an antibody variable region comprising a specific sequence, it is also intended to cover the antibody variable region consisting of the specific sequence.
[0038] The "affinity" or "binding affinity" mentioned herein is understood according to the common meaning in the art, and is used to reflect the strength and / or stability of the binding sites between an antigen and an antibody or antigen-binding fragment.
[0039] "Specifically recognize", "specifically recognize in", "specifically bind to" or "specifically bind to", "bind to", "specifically target" a specific antigen or epitope, or "have specificity" or "can bind to" a specific antigen or epitope means to distinguish it from non-specific interactions, and this specific binding or specific recognition effect can be measured by some methods commonly used in the art. The ability of an antibody to bind to an antigen can be measured by enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art. For example, cells carrying antigens can be detected by flow cytometry, and the competitive binding between the test antibody and the labeled antibody can be detected by measuring the positive rate index of the cells. Since the spatial structure of the antigen on the cell surface is closer to the form existing in the body, this method can better reflect the real situation. In conjunction with specific embodiments of the present invention, the provided antibodies have endocytosis and exhibit endocytosis with EC50 values of ≤10nM, ≤9nM, ≤8nM, ≤7nM, ≤6nM, ≤5nM, ≤4nM, ≤3nM, ≤2nM, ≤1nM, ≤0.9nM, ≤0.8nM, ≤0.7nM, ≤0.6nM, ≤0.5nM, ≤0.4nM, ≤0.3nM, ≤0.2nM, ≤0.1nM, ≤0.05nM, ≤0.01nM, ≤0.005nM, ≤0.001nM. In addition, the binding activity of the antibody to the antigen can also be measured by surface plasmon resonance (SPR) or bio-film interferometry (BLI).
[0040] "Humanized" antibodies generally refer to antibodies whose antigen-binding portion is derived from a non-human species and whose structure and sequence are based on a portion of a human immunoglobulin molecule. For example, in a humanized antibody, the entire antibody, excluding the CDRs, is encoded by a polynucleotide of human origin, which retains antigen-binding activity while reducing immunogenicity.
[0041] The term "therapeutic agent" refers to any substance or entity that can play a therapeutic role (e.g., treat, prevent, alleviate or inhibit any disease and / or cancer), including but not limited to: chemotherapeutic agents, radiotherapeutic agents, immunotherapeutic agents, thermal therapeutic agents, etc.
[0042] Epitope peptide
[0043] Select an amino acid sequence that is not contained in the amino acid sequence of a mammalian cell membrane protein or secretory protein under the natural state as an antigenic epitope polypeptide, modify the surface of tumor cells and / or cancer cells, so that the antigenic epitope polypeptide is modified on the surface of tumor cells and / or cancer cells through expression, thereby tumor cells and / or cancer cells can be distinguished from normal cells. According to a specific embodiment, in order to modify the antigenic epitope polypeptide on the surface of tumor cells and / or cancer cells, the extracellular antigenic determinant, the spacer portion and the transmembrane portion can be operably connected as needed to jointly constitute a marker polypeptide. The antigenic epitope polypeptide, as a part of the extracellular antigenic determinant, can be provided with one or more as needed. By expressing the marker polypeptide on tumor cells and / or cancer cells, the antigenic epitope polypeptide is modified on the surface of tumor cells and / or cancer cells. When describing the expression of a protein or polypeptide on tumor cells or cancer cells or normal cells, or when expressing in tumor cells or cancer cells or normal cells, the position of the protein or polypeptide on the cell is not specifically limited (i.e., it is not specifically limited to expression in the cell or on the cell or on the cell surface). Those skilled in the art can determine the expression location of a protein or polypeptide based on common technical knowledge, for example, the extracellular antigenic determinant is expressed on the cell surface, and the transmembrane portion is expressed on the cell membrane. The mentioned marker polypeptide and its contained extracellular antigenic determinant, spacer portion and transmembrane portion and other polypeptide sequences are all recorded in the PCT patent application with international application number PCT / CN2019 / 102480 and international publication number WO2020038490A, which can be cited or partially cited in this article as needed. The term "extracellular antigenic determinant" refers to the portion of the marker polypeptide containing the antigenic epitope polypeptide located outside the cell membrane when it is expressed on the cell surface.
[0044] According to a specific embodiment, the amino acid sequence of the antigenic epitope polypeptide is derived from the amino acid sequence of a protein existing in nature, or is an artificially synthesized amino acid sequence that does not exist in nature. Among them, proteins existing in nature include proteins in mammalian cells and proteins of other organisms except mammals. Proteins of other organisms except mammals include viral proteins, bacterial proteins, fungal proteins, protozoan proteins, plant proteins, and other animal proteins except mammals. In some embodiments, the amino acid sequence of the antigenic epitope polypeptide is derived from the amino acid sequence of the following tags: Myc tag, HA tag, Strep tag I, Strep tag II, Flag tag, HAT tag, S tag, S1 tag, protein C tag, tag-100 tag, E2 tag, TAP tag, HSV tag, KT3 tag, V5 tag, VSV-G tag, His tag or RFP tag, etc. The amino acid sequences and nucleotide sequences of these tags are all known and can be found in the public databases commonly used in the art.
[0045] In some preferred embodiments, the amino acid sequence of the antigenic epitope polypeptide is derived from the amino acid sequence of the following tags: human Myc tag (the corresponding tag polypeptide is denoted as TT1), influenza virus HA tag (the corresponding tag polypeptide is denoted as TT2), Strep tag II (the corresponding tag polypeptide is denoted as TT3), or Strep tag I. The amino acid sequence of the Strep tag I or Strep tag II mentioned above is at least 3 amino acids in length, for example, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, 10 amino acids, or 11, 12, 13, 14, or 15 amino acids, and may include amino acids derived from the sequence shown in NWSHPQFEK (SEQ ID NO: 26) or AWRHPQFGG (SEQ ID NO: 27), or may be a partial sequence or a combination of partial sequences of these sequences. More specifically, the amino acid sequence of Strep tag II may be, for example, WSHPQFEK (SEQ ID NO: 28) or NWSHPQFEK (SEQ ID NO: 26). The amino acid sequence of the Strep tag I mentioned above can be, for example, AWRHPQFGG (SEQ ID NO: 27). Preferably, the amino acid sequence of the antigenic epitope polypeptide is consistent with the amino acid sequence of positions 410 to 419 of the human Myc protein; or the amino acid sequence of the antigenic epitope polypeptide is consistent with the amino acid sequence of positions 119 to 127 of the influenza virus HA protein; or the amino acid sequence of the antigenic epitope polypeptide is consistent with Strep tag II (for a detailed description of Strep tag II, see the document “Molecular Interaction Between the Strep-tag Affinity Peptide and its Cognate Target, Streptavidin, Thomas GMSchmidt, Jurgen Koepke, Ronald Frank and Arne Skerra”). In other embodiments of the present invention, the amino acid sequence of the antigenic epitope polypeptides of TT1 and TT2 can be extended by no more than 10 amino acids upstream and downstream of the above sequence. The amino acid sequence of the human Myc protein can be the amino acid sequence numbered P01106 isoform 1 in UniProtKB. The amino acid sequence of the influenza virus HA protein may be the amino acid sequence numbered Q03909 in UniProtKB.
[0046] In some specific embodiments, the amino acid sequence of the extracellular antigenic determinant of the marker polypeptide includes the amino acid sequence of one or more epitope polypeptides, wherein when the amino acid sequence of the extracellular antigenic determinant of the marker polypeptide includes the amino acid sequence of multiple epitope polypeptides, each two adjacent epitope polypeptides are operably connected, for example, by using a linker, or directly connected without using a linker. The amino acid sequence of the linker can be (for example): G (as used in marker polypeptides C1&2a, C1&2b), GGS (as used in C1&2a, C1&2b), GGGGSGGGGS (as used in TT1-TT3).
[0047] In order to enhance the immunogenicity of the marker polypeptide, the extracellular antigenic determinant region of the marker polypeptide preferably comprises n antigenic epitope polypeptides, wherein n is an integer greater than or equal to 1, for example, n = 1, 2, 3, 4, ... Preferably, n is an integer between 1 and 10; more preferably, n is an integer between 2 and 5; and even more preferably, n = 2 or 3.
[0048] According to a specific embodiment, the extracellular antigenic determinant region of the marker polypeptide may comprise one, two, three, four or five repeats of an antigenic epitope polypeptide derived from Strep tag I or Strep tag II.
[0049] According to a specific embodiment, the sequence of the antigenic epitope polypeptide is shown as SEQ ID NO: 24 or SEQ ID NO: 25.
[0050] According to a specific embodiment, the extracellular antigenic determinant and the transmembrane portion are connected by a spacer. The structure of this region should be flexible, allowing the extracellular antigenic determinant to adapt to different orientations, thereby promoting recognition and binding by the corresponding multispecific antibody. The simplest form of the spacer is the hinge region of immunoglobulin IgG1, or it can be a portion of the CH2CH3 region of an immunoglobulin. Through research and experimental exploration, it has been found that the spacer is preferably derived from the hinge region of CD8α, and the transmembrane region is preferably derived from the transmembrane region of CD8α. Preferably, the spacer and transmembrane portion constitute a spacer transmembrane portion, and the amino acid sequence of the spacer transmembrane portion is identical to the amino acid sequence of positions Y to 210 of CD8α, with 118≤Y≤128, where Y is an integer. The UniProtKB number for the amino acid sequence of CD8α can be P01732. In other words, the amino acid sequence of the spacer transmembrane portion is preferably selected from amino acids 118-210 of CD8α and includes amino acids 128-210. For example, the amino acid sequence of the spacer transmembrane portion is as shown in any one of the following amino acid sequence groups: amino acids 118-210, amino acids 119-210, amino acids 120-210, amino acids 121-210, amino acids 122-210, amino acids 123-210, amino acids 124-210, amino acids 125-210, amino acids 126-210, amino acids 127-210, or amino acids 128-210 of CD8α.
[0051] The transmembrane portion can be any type I transmembrane region sequence, and the type I transmembrane region sequence mentioned refers to a single transmembrane sequence, and the N-terminus of the peptide chain is located outside the cell membrane, and the C-terminus of the peptide chain is located inside the cell membrane. According to a specific embodiment, the transmembrane portion is derived from the transmembrane region of CD8, CD3ζ, CD4 or CD28, and its full-length amino acid sequence and nucleotide sequence are all known and can be queried from public databases commonly used in this field. It is also preferred that the transmembrane portion is derived from the transmembrane region of human CD8α. CD8 is a transmembrane glycosylated membrane protein composed of two subunits, α and β, which work together with T cell surface receptors to bind T cells to specific antigens. CD8 specifically binds to MHC I and mediates the killing effect of cytotoxic T cells. The transmembrane region is usually a hydrophobic α helix that spans the cell membrane.
[0052] The definitions of the terms "spacer portion" and "transmembrane portion" used in this article are known in the art. For details, please refer to "Introduction to Immunology, Yu Shanqian, Higher Education Press, 2008"; and "Immunobiology, 7th Edition, Kenneth Murphy, Paul Travers, Mark Walport, etc."
[0053] The present invention further discovered that a tagged polypeptide can simultaneously express two antigenic polypeptides. Specifically, the present invention designed a tagged polypeptide, Cl&2a, whose antigenic determinant region contains three repeats of each of a Myc tag and an HA tag. The present invention also designed a tagged polypeptide, Cl&2b, whose antigenic determinant region contains two repeats of each of a Myc tag and an HA tag. To further stabilize the expression of the tagged polypeptide on the cell membrane surface, a TIGIT spacer was added to the intercellular region of Cl&2b, wherein the amino acid sequence of the added spacer is consistent with the amino acid sequence of TIGIT at positions 24 to 140. The amino acid sequence of TIGIT is derived from UniProt KB-Q495A1.
[0054] According to a specific embodiment, the amino acid sequence of the marker polypeptide is as shown in SEQ ID NO: 18 (corresponding to TT1), 19 (corresponding to TT2), 20 (corresponding to TT3), 21 (corresponding to Cl&2a) or 22 (corresponding to Cl&2b).
[0055] In some embodiments, a marker polypeptide can be expressed on tumor cells / cancer cells using a recombinant virus as a vector. The recombinant virus genome contains the marker polypeptide coding sequence, and the marker polypeptide is expressed on tumor cells / cancer cells via the recombinant virus. The nucleic acid encoding the marker polypeptide of the present invention preferably also includes a signal peptide coding sequence 5' to the 5' end of the marker polypeptide coding sequence. The signal peptide functions to direct the secretion of the target protein to the cell surface. The present invention has discovered that combining the extracellular antigenic determinant with a signal peptide derived from the GM-CSF α chain enables expression of the marker polypeptide on the surface of tumor cells. The GM-CSF α chain signal peptide is a leader sequence that targets the marker polypeptide of the present invention to the secretory pathway. Its coding sequence is first translated into protein within the cell along with the coding sequence for the marker polypeptide, directing the synthesized protein into the intracellular secretory pathway. Prior to cell surface expression of the marker polypeptide, the signal peptide is removed. The full-length amino acid and nucleotide sequences of the GM-CSF α chain are known and can be retrieved from publicly available databases commonly used in the art. Preferably, the amino acid sequence of the signal peptide is selected from amino acids 1 to 22 of the human GM-CSF α chain. More preferably, the amino acid sequence of the signal peptide is shown in SEQ ID NO: 23. The amino acid sequence of the GM-CSF α chain is from UniProtKB-P15509.
[0056] The recombinant virus mentioned includes a selection of replicative repeat oncolytic viruses or replication-deficient recombinant viruses. According to the embodiment, the recombinant oncolytic virus is derived from a genetically mutated virus with oncolytic effect and a wild-type virus with oncolytic effect; preferably, the recombinant oncolytic virus is derived from an adenovirus, poxvirus, herpes simplex virus, measles virus, Semliki Forest virus, vesicular stomatitis virus, poliovirus, retrovirus, reovirus, Seneca Valley virus, Echovirus, Coxsackie virus, Newcastle disease virus and Maraba virus with oncolytic effect. The oncolytic virus can selectively replicate in tumor cells, thereby expressing the marker polypeptide in tumor cells or cancer cells, so that the oncolytic virus significantly enhances the expression of antigen epitope polypeptides on the surface of tumor cells while killing tumor cells or cancer cells, and then combines with antibody-bridged immune cells to show a synergistic therapeutic effect.
[0057] According to a specific embodiment, the nucleic acid of the above-mentioned marker polypeptide coding sequence can be inserted into the genome of the recombinant virus. According to a specific embodiment, the recombinant oncolytic virus is a recombinant oncolytic poxvirus with TK gene and VGF gene functional defects. The TK gene can be made functionally defective by inserting an exogenous nucleotide sequence. The VGF gene can be made functionally defective by gene knockout or insertion of an exogenous nucleotide sequence, but the VGF gene is preferably knocked out. According to a specific embodiment, the recombinant virus is configured for intratumoral injection, intravenous administration, intraperitoneal injection or intracranial injection.
[0058] According to specific embodiments, the coding sequence is DNA or RNA, including mRNA transcribed from DNA.
[0059] According to a specific embodiment, the DNA is formulated for administration by intratumoral injection, intravenous injection, intraperitoneal injection or intracranial injection; the mRNA is formulated for administration by intratumoral injection, intravenous injection, intraperitoneal injection or intracranial injection.
[0060] Antibody drug conjugates and their uses
[0061] The present invention provides the use of an antibody or antigen-binding fragment thereof targeting an antigenic epitope polypeptide in the preparation of an antibody-drug conjugate for treating cancer and / or tumors. The present invention also provides an antibody-drug conjugate targeting an antigenic epitope polypeptide, comprising an antibody or antigen-binding fragment thereof targeting an antigenic epitope polypeptide conjugated to one or more therapeutic agents. The antigenic epitope polypeptide is the antigenic epitope polypeptide mentioned above. According to a specific embodiment, in a natural state, the amino acid sequence of a mammalian cell membrane protein or secretory protein does not contain the amino acid sequence of the antigenic epitope polypeptide; compared to normal cells, the antigenic epitope polypeptide is differentially and highly expressed on tumor cells / cancer cells; the antibody or antigen-binding fragment specifically binds to the antigenic epitope polypeptide on the tumor cells / cancer cells and exhibits endocytosis with an EC50 of ≤100 nM, for example, EC50 ≤90 nM, EC50 ≤80 nM, EC50 ≤70 nM, EC50 ≤60 nM, EC50 ≤50 nM, EC50 ≤40 nM, EC50 ≤30 nM, EC50 ≤20 nM, EC50 ≤10 nM, EC50 ≤5 nM, EC50 ≤1 nM, EC50 ≤0.5 nM, EC50 ≤0.1 nM, etc. The antigenic epitope polypeptide mentioned is the antigenic epitope polypeptide mentioned above. The term "differentially highly expressed" refers to the high expression of the antigenic epitope polypeptide in tumor cells / cancer cells, the absence or low expression of the antigenic epitope polypeptide in normal human cells, and the significant difference in expression between tumor cells / cancer cells and normal human cells. The significant difference refers to a statistically significant p-value of less than or equal to 0.05.
[0062] According to a specific embodiment, the antigenic epitope polypeptide has one or more sequences derived from Strep tag I or Strep tag II. The "plurality" mentioned includes two, for example, it can be two, three, four, five, six, seven, etc. It can be multiple repeated Strep tag I, or multiple repeated Strep tag II, or any combination of strep tag I and strep tag II. It can be the entire sequence of multiple repeated Strep tag I or Strep tag II, or a partial sequence. According to a specific embodiment, the antigenic epitope polypeptide has one or more repeated sequences derived from Strep tag I or Strep tag II. The "repeat" mentioned refers to multiple repeats of Strep tag I, or multiple repeats of Strep tag II. According to a specific embodiment, the antigenic epitope polypeptide has the sequence shown in SEQ ID NO:24 or SEQ ID NO:25.
[0063] According to a specific embodiment, the form of the antibody or its antigen-binding fragment mentioned is not particularly required, including but not limited to monoclonal antibodies, polyclonal antibodies, natural antibodies, engineered antibodies, recombinant proteins, bispecific antibodies, multispecific antibodies, monovalent antibodies, multivalent antibodies, complete antibodies, Fab, Fd, scFv, F(ab')2 fragments, Fab' fragments, Fv fragments, and single-chain antibodies. According to a specific embodiment, the antibody or its antigen-binding fragment also includes the constant region of an immunoglobulin, and the constant region of the immunoglobulin is IgG1, IgG2, IgG3, IgG4, or a variant thereof. For example, the constant region of an immunoglobulin includes Fc or a variant thereof. The Fc mentioned can be derived from a natural Fc or a modified Fc. The natural Fc can be of any origin, including but not limited to mouse, primate, or human, preferably a human Fc region. The human Fc region mentioned can be obtained from a public database. Mutated Fc include but are not limited to L234A / L235A, L234F / L235E / P331S, G236R / L328R, L234A / L245A / P329G, etc. By mutating Fc, the binding of Fc to relevant receptors can be regulated, thereby regulating the function of ADCC.
[0064] According to specific embodiments, the amino acid sequence of the light chain of the antigen-binding domain targeting TT3 is identical to that of an anti-Strep Tag II antibody (see, for example, patent document EP2871189A1), and the amino acid sequence of the heavy chain is identical to that of an anti-Strep Tag II antibody (see, for example, patent document EP2871189A1). In conjunction with the specific embodiments of patent document EP2871189A1, the disclosed antibody capable of specifically targeting TT3 comprises a heavy chain variable region set forth in SEQ ID NO:7 and a light chain variable region set forth in SEQ ID NO:8. This antibody is capable of specifically recognizing and binding to TT3. To reduce immunogenicity, the antibody comprising the heavy chain variable region set forth in SEQ ID NO:7 and the light chain variable region set forth in SEQ ID NO:8 can be humanized. The humanized antibody retains high affinity for TT3. According to specific embodiments, the humanized antibody comprises a heavy chain variable region set forth in SEQ ID NO:1, 2, or 3 and a light chain variable region set forth in SEQ ID NO:4, 5, or 6. The sequences of the heavy chain variable regions and light chain variable regions mentioned above can be freely combined, and the resulting antibodies have been shown to exhibit high affinity activity against TT3. Furthermore, any humanized heavy chain variable region can be combined with the light chain variable region set forth in SEQ ID NO:8, and any humanized light chain variable region can be combined with the heavy chain variable region set forth in SEQ ID NO:7, to specifically target TT3. The antibodies or antigen-binding fragments thereof specifically targeting TT3 mentioned herein refer to antigenic epitope polypeptides or extracellular antigenic determinants specifically targeting TT3. According to specific embodiments, the antibodies or antigen-binding fragments specifically targeting TT3 specifically target the sequence set forth in SEQ ID NO:25.
[0065] According to a specific embodiment, an antibody or antigen-binding fragment thereof targeting the TT3 antigen comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein the amino acid sequences of HCDR1, HCDR2, and HCDR3 are the CDR1, CDR2, and CDR3 of the heavy chain variable region as set forth in SEQ ID NO:7, and the amino acid sequences of LCDR1, LCDR2, and LCDR3 are the CDR1, CDR2, and CDR3 of the light chain variable region as set forth in SEQ ID NO:8. According to a specific embodiment, the CDR sequences of the antibody or antigen-binding fragment targeting TT3 vary according to different definition schemes. For example, they may be defined according to the IMGT definition scheme, as shown in SEQ ID NOs:12-17. Alternatively, they may be defined according to the Kabat, Chothia, AbM, Contact, and other definition schemes. Different CDR sequences obtained according to different definition schemes are all within the scope of protection of the present invention.
[0066] According to specific embodiments, an antibody or antigen-binding fragment thereof targeting TT3 comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is selected from the sequence set forth in SEQ ID NO: 1, 2, 3, or 7, and the light chain variable region is selected from the sequence set forth in SEQ ID NO: 4, 5, 6, or 8. The heavy chain variable region can be linked to a heavy chain constant domain, and the light chain variable region can be linked to a light chain constant domain to form an IgG antibody. According to specific embodiments, the sequence of the heavy chain constant domain is set forth in SEQ ID NO: 9 or 10. According to specific embodiments, the sequence of the light chain constant domain is set forth in SEQ ID NO: 11.
[0067] According to a specific embodiment, the antibody or antigen-binding fragment thereof targeting TT3 has a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain variable region as shown in SEQ ID NO: 4; or has a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain variable region as shown in SEQ ID NO: 5; or has a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain variable region as shown in SEQ ID NO: 6; or has a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain variable region as shown in SEQ ID NO: 8; or has a heavy chain variable region as shown in SEQ ID NO: 2 and a light chain variable region as shown in SEQ ID NO: 4; or has a heavy chain variable region as shown in SEQ ID NO: 2 and a light chain variable region as shown in SEQ ID NO: 5; or has a heavy chain variable region as shown in SEQ ID NO: 2 and a light chain variable region as shown in SEQ ID NO: 6; or has a heavy chain variable region as shown in SEQ ID NO: 2 and a light chain variable region as shown in SEQ ID NO: 8; or has a heavy chain variable region as shown in SEQ ID NO: 3 and a light chain variable region as shown in SEQ ID NO: 4; or has a heavy chain variable region as shown in SEQ ID NO: 3 and a light chain variable region as shown in SEQ ID NO: 4 NO:5; or a heavy chain variable region set forth in SEQ ID NO:3 and a light chain variable region set forth in SEQ ID NO:6; or a heavy chain variable region set forth in SEQ ID NO:3 and a light chain variable region set forth in SEQ ID NO:8; or a heavy chain variable region set forth in SEQ ID NO:7 and a light chain variable region set forth in SEQ ID NO:8; or a heavy chain variable region set forth in SEQ ID NO:7 and a light chain variable region set forth in SEQ ID NO:4; or a heavy chain variable region set forth in SEQ ID NO:7 and a light chain variable region set forth in SEQ ID NO:5; or a heavy chain variable region set forth in SEQ ID NO:7 and a light chain variable region set forth in SEQ ID NO:6. The heavy chain variable region may be linked to a heavy chain constant domain set forth in SEQ ID NO:9 or 10, and the light chain variable region may be linked to a light chain constant domain set forth in SEQ ID NO:11.
[0068] The amino acid sequence mentioned is shown below:
[0069] According to a specific embodiment, the antibody or antigen-binding fragment thereof targeting TT3 is an IgG1 antibody, numbered Ab-1hu, which has a heavy chain variable region set forth in SEQ ID NO: 1 and a light chain variable region set forth in SEQ ID NO: 4, the heavy chain variable region is linked to the heavy chain constant domain set forth in SEQ ID NO: 9, and the light chain variable region is linked to the light chain constant domain set forth in SEQ ID NO: 11. According to a specific embodiment, the antibody or antigen-binding fragment thereof targeting TT3 is an IgG1 antibody, numbered Ab-2hu, which has a heavy chain variable region set forth in SEQ ID NO: 2 and a light chain variable region set forth in SEQ ID NO: 5, the heavy chain variable region is linked to the heavy chain constant domain set forth in SEQ ID NO: 9, and the light chain variable region is linked to the light chain constant domain set forth in SEQ ID NO: 11. According to a specific embodiment, the antibody or antigen-binding fragment thereof targeting TT3 is an IgG1 antibody, numbered Ab-3hu, comprising a heavy chain variable region set forth in SEQ ID NO: 3 and a light chain variable region set forth in SEQ ID NO: 6, wherein the heavy chain variable region is linked to the heavy chain constant domain set forth in SEQ ID NO: 9, and the light chain variable region is linked to the light chain constant domain set forth in SEQ ID NO: 11. According to a specific embodiment, the antibody or antigen-binding fragment thereof targeting TT3 is an IgG1 antibody with L234F / L235E / P331S mutations in the Fc region, numbered Ab-3hu-mu, and having an amino acid sequence comprising a heavy chain variable region set forth in SEQ ID NO: 3 and a light chain variable region set forth in SEQ ID NO: 6, wherein the heavy chain variable region is linked to the heavy chain constant domain set forth in SEQ ID NO: 10, and the light chain variable region is linked to the light chain constant domain set forth in SEQ ID NO: 11. According to a specific embodiment, the antibody or antigen-binding fragment thereof targeting TT3 is an IgG1 antibody, numbered Ab-4hu, which has a heavy chain variable region set forth in SEQ ID NO: 1 and a light chain variable region set forth in SEQ ID NO: 5, the heavy chain variable region being linked to the heavy chain constant domain set forth in SEQ ID NO: 9, and the light chain variable region being linked to the light chain constant domain set forth in SEQ ID NO: 11. According to a specific embodiment, the antibody or antigen-binding fragment thereof targeting the TT3 antigen, Ab-5hu, has a heavy chain variable region set forth in SEQ ID NO: 1 and a light chain variable region set forth in SEQ ID NO: 6, the heavy chain variable region being linked to the heavy chain constant domain set forth in SEQ ID NO: 9, and the light chain variable region being linked to the light chain constant domain set forth in SEQ ID NO: 11.According to a specific embodiment, the antibody or antigen-binding fragment thereof targeting TT3 is an IgG1 antibody, numbered Ab-6hu, which has a heavy chain variable region set forth in SEQ ID NO: 2 and a light chain variable region set forth in SEQ ID NO: 4, the heavy chain variable region is linked to the heavy chain constant domain set forth in SEQ ID NO: 9, and the light chain variable region is linked to the light chain constant domain set forth in SEQ ID NO: 11. According to a specific embodiment, the antibody or antigen-binding fragment thereof targeting TT3 is an IgG1 antibody, numbered Ab-7hu, which has a heavy chain variable region set forth in SEQ ID NO: 2 and a light chain variable region set forth in SEQ ID NO: 6, the heavy chain variable region is linked to the heavy chain constant domain set forth in SEQ ID NO: 9, and the light chain variable region is linked to the light chain constant domain set forth in SEQ ID NO: 11. According to a specific embodiment, the antibody or antigen-binding fragment thereof targeting TT3 is an IgG1 antibody, numbered Ab-8hu, which has a heavy chain variable region set forth in SEQ ID NO: 3 and a light chain variable region set forth in SEQ ID NO: 4, the heavy chain variable region being linked to the heavy chain constant domain set forth in SEQ ID NO: 9, and the light chain variable region being linked to the light chain constant domain set forth in SEQ ID NO: 11. According to a specific embodiment, the antibody or antigen-binding fragment thereof targeting TT3 is an IgG1 antibody, numbered Ab-9hu, which has a heavy chain variable region set forth in SEQ ID NO: 3 and a light chain variable region set forth in SEQ ID NO: 5, the heavy chain variable region being linked to the heavy chain constant domain set forth in SEQ ID NO: 9, and the light chain variable region being linked to the light chain constant domain set forth in SEQ ID NO: 11.
[0070] The antibodies or antigen-binding fragments thereof mentioned herein are generally separable or recombinant. "Separable" means capable of being identified and separated and / or recovered from cells or cell cultures expressing the polypeptide or protein. Typically, the isolated polypeptide will be prepared by at least one purification step. "Isolated antibody" means substantially free of other antibodies or antigen-binding fragments having different antigenic specificities. "Recombinant" means that the antibody can be produced in an exogenous host cell using genetic recombination techniques.
[0071] The aforementioned antibodies or antigen-binding fragments thereof can be obtained by inserting the nucleotides encoding them into a replicable expression vector and expressing them in a host cell or a cell-free expression system. A construct can be obtained by inserting the nucleotides encoding the antibody or antigen-binding fragment into a replicable expression vector. A variety of methods commonly used in the art can be used to obtain constructs, including in vitro recombinant DNA techniques, DNA synthesis techniques, in vivo recombination techniques, and the like. For example, a polynucleotide can be inserted into the multiple cloning site of an expression vector to form a construct. The construct can contain various operators, such as promoters, terminators, and marker genes, as needed, which are operably linked to the polynucleotide. Promoters are generally used to provide a signal to initiate transcription. Promoters can be selected from the lactose promoter (Lac), Trp promoter, Tac promoter, or phage PL and PR promoters as needed. Terminators provide a signal to terminate transcription during the transcription process, and marker genes in the construct are often used for screening. Of course, enhancers can also be included as needed to enhance protein expression. The expression vector is not particularly limited and can be any commercially available expression vector or an artificially modified expression vector, such as a plasmid, phage, or virus. The virus may be a plant cell virus, a mammalian cell virus, etc. The construct may express antibodies or proteins in vitro, or may be transferred into cells to express antibodies or proteins.
[0072] Any cell suitable for expressing a polynucleotide or construct for antibody or protein expression can be used as a host cell. Host cells can be prokaryotic cells, such as bacterial cells, or eukaryotic cells, such as yeast cells or mammalian cells. Common host cells include yeast cells, CHO cells, HEK-293 cells, COS cells, and Drosophila S2 or Sf9 insect cells. Host cells containing the polynucleotide or construct can be obtained using methods commonly used in the art, such as microinjection, electroporation, chemical transfection, and viral-mediated transformation. Antibodies or antigen-binding fragments targeting the TT3 antigen can be obtained by culturing the above-mentioned host cells and collecting the culture. The collected antibody or antigen-binding fragment can be purified to obtain a substantially pure product. "Substantially pure" means that the purity of the antibody or antigen-binding fragment is greater than 95%, greater than 96%, greater than 97%, greater than 98%, greater than 99%, or even greater than 99.5%, 99.6%, 99.7%, or 99.8%.
[0073] The provided antibody-drug conjugates also include one or more therapeutic agents coupled to the antibody or antigen-binding fragment via a linker. The linker used to couple the therapeutic agent to the antibody or antigen-binding fragment can be a linker commonly used in the art. It can be linked to the antibody by any means known in the art, preferably via a sulfhydryl group and / or an amino group. In some embodiments, the antibody of the present invention is linked to the linker via a sulfhydryl group. The linker used in the present invention can be a cleavable linker (i.e., a linker that can cleave in the in vivo environment) or a non-cleavable linker. A cleavable linker can cleave within or on the target cell, thereby releasing the drug. In some embodiments, the linker of the present invention has good stability, significantly reducing the release of the drug during delivery to the target (e.g., in the blood), thereby reducing side effects and toxicity. In some embodiments, the linker of the present invention is selected from a cleavable linker, such as a disulfide-based linker (which selectively cleaves in tumor cells with a higher concentration of sulfhydryl groups), a peptide linker (which is cleaved by enzymes in tumor cells), or a hydrazone linker. In some embodiments, the linker used is a non-cleavable linker, such as a thioether linker. For example, the linker used is a cleavable mc-vc-PAB linker, valine-citrulline (vc) or valine-alanine (va) and a non-cleavable mc linker (maleimidoacetyl). For example, examples of linker therapeutic agents formed by a linker and a therapeutic agent can include mc-vc-PAB-MMAE (which can be abbreviated as mc-vc-MMAE and vc-MMAE), mc-MMAF and mc-vc-MMAF.
[0074] The therapeutic agent is selected from the group consisting of cytotoxic molecules, immunopotentiators and radioisotopes. According to a specific embodiment, the cytotoxic molecule is selected from the group consisting of tubulin inhibitors or DNA damaging agents.
[0075] Tubulin inhibitors can disrupt microtubule assembly and affect mitosis. Microtubules are an important component of the cytoskeleton and play an important role in the process of cell division. Since tumor cells maintain rapid proliferation, tubulin inhibitors that interfere with tumor cell mitosis have become one of the directions of tumor drug research and development. The mentioned tubulin inhibitors are selected from dolastatin or auristatin cytotoxic molecules, maytansine cytotoxic molecules; the mentioned auristatin cytotoxic molecules are selected from MMAE (monomethyl auristation E) or MMAF (monomethyl auristation F) or their derivatives, and the maytansine cytotoxic molecules are selected from DM1, DM4 or their derivatives. MMAE or MMAF are typical agents that promote microtubule polymerization, acting on the β-subunit of the α-β tubulin dimer, causing microtubule growth to be unregulated, and are effective payloads. The DNA damaging agent is selected from calicheamicins, duocarmycins, anthramycin derivatives PBD, camptothecins and camptothecin derivatives, SN-38, and Dxd.
[0076] According to a specific embodiment, the present invention provides an antibody drug conjugate having the general structural formula Ab-(LU)n, wherein:
[0077] The Ab represents an antibody or antigen-binding fragment thereof targeting an antigen epitope polypeptide, the U is an active drug unit, the L is any linking group, and the L is covalently linked to the Ab and the U, respectively; n is an integer selected from 1, 2, 3, 4, 5, 6, 7 or 8; 1, 2, 3, 4, 5, 6, 7 or 8 Us are linked to the Ab through one or more Ls.
[0078] According to a specific embodiment, the L is covalently linked to an amino residue or a sulfhydryl residue on the Ab; preferably, the L is covalently linked to a sulfhydryl residue on the Ab; more preferably, the L is covalently linked to a sulfhydryl residue formed after the interchain disulfide bond on the Ab is opened.
[0079] According to a specific embodiment, the L comprises a cleavable linker and a non-cleavable linker. According to a specific embodiment, the cleavable linker comprises 2 to 20 amino acid units, preferably, the amino acid units are selected from phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid, aspartic acid, valine-citrulline (Val-Cit), alanine-alanine-asparagine (Ala-Ala-Asn), glycine-glycine-lysine (Gly-Gly-lys), valine-lysine (Val-lys), valine-alanine (Val-Ala), valine-phenylalanine (Val-Phe) or glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly) or a combination thereof.
[0080] According to a specific embodiment, the U is selected from the general formula (I) or a pharmaceutically acceptable salt or solvate thereof:
[0081] Among them, in the general formula (I)
[0082] R1 and R2 are each independently selected from H or C1-C6 alkyl;
[0083] R3 is selected from C1-C8 alkyl;
[0084] R4 and R5 are each independently selected from H, C1-C6 alkyl, aryl, or R4 and R5 form a C3-C8 membered ring;
[0085] R6 is selected from C1-C8 alkyl;
[0086] R7 is selected from C1-C8 alkyl;
[0087] R8 is selected from H or C1-C8 alkyl;
[0088] R9 is selected from H, C1-C8 alkyl, -OH, -COOH, -COO(C1-C6 alkyl), -CONH(C1-C6 alkyl), C5-C7 heterocycle;
[0089] R 10 is selected from H, -OH, or a bond, when R 10 When it is a bond, the OR10 formed is =O;
[0090] R 11 Selected from H, C1-C6 alkyl, or -OH.
[0091] According to a preferred embodiment, R1 is independently selected from H, methyl, or ethyl. According to a specific embodiment, R3 is methyl, ethyl, or isopropyl. According to a specific embodiment, R4 and R5 are independently selected from H, methyl, or ethyl. According to a specific embodiment, R6 is H, methyl, or ethyl. R7 is methyl, ethyl, isopropyl, n-butyl, or isobutyl. According to a specific embodiment, R8 is H, methyl, or ethyl. According to a specific embodiment, R9 is methyl, -COOH, or -CONH-CH3.
[0092] According to a specific embodiment, R 10 It is H or -OH.
[0093] According to a specific embodiment, R 11 It is H or -OH.
[0094] According to a specific embodiment, U is selected from the following structures:
[0095] According to a specific embodiment, said L is selected from the following structures:
[0096] According to a specific embodiment, the Ab includes a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3, wherein: the amino acid sequences of HCDR1, HCDR2 and HCDR3 are CDR1, CDR2 and CDR3 of the heavy chain variable region as shown in SEQ ID NO: 7, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 are CDR1, CDR2 and CDR3 of the light chain variable region as shown in SEQ ID NO: 8.
[0097] According to a specific embodiment, the Ab comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region is selected from the sequence shown in SEQ ID NO: 1, 2, 3 or 7, and the light chain variable region is selected from the sequence shown in SEQ ID NO: 4, 5, 6 or 8.
[0098] According to a specific embodiment, the Ab has a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain variable region as shown in SEQ ID NO: 4. According to a specific embodiment, the Ab has a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain variable region as shown in SEQ ID NO: 5. According to a specific embodiment, the Ab has a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain variable region as shown in SEQ ID NO: 6. According to a specific embodiment, the Ab has a heavy chain variable region as shown in SEQ ID NO: 2 and a light chain variable region as shown in SEQ ID NO: 4. According to a specific embodiment, the Ab has a heavy chain variable region as shown in SEQ ID NO: 2 and a light chain variable region as shown in SEQ ID NO: 5. According to a specific embodiment, the Ab has a heavy chain variable region as shown in SEQ ID NO: 2 and a light chain variable region as shown in SEQ ID NO: 6. According to a specific embodiment, the Ab has a heavy chain variable region as shown in SEQ ID NO: 3 and a light chain variable region as shown in SEQ ID NO: 4. According to a specific embodiment, the Ab has a heavy chain variable region as shown in SEQ ID NO: 3 and a light chain variable region as shown in SEQ ID NO: 5. According to a specific embodiment, the Ab has a heavy chain variable region set forth in SEQ ID NO: 3 and a light chain variable region set forth in SEQ ID NO: 6. According to a specific embodiment, the Ab has a heavy chain variable region set forth in SEQ ID NO: 7 and a light chain variable region set forth in SEQ ID NO: 8. According to a specific embodiment, the Ab has a heavy chain variable region set forth in SEQ ID NO: 7 and a light chain variable region set forth in SEQ ID NO: 4. According to a specific embodiment, the Ab has a heavy chain variable region set forth in SEQ ID NO: 7 and a light chain variable region set forth in SEQ ID NO: 5. According to a specific embodiment, the Ab has a heavy chain variable region set forth in SEQ ID NO: 7 and a light chain variable region set forth in SEQ ID NO: 6. According to a specific embodiment, the Ab has a heavy chain variable region set forth in SEQ ID NO: 1 and a light chain variable region set forth in SEQ ID NO: 8. According to a specific embodiment, the Ab has a heavy chain variable region set forth in SEQ ID NO: 2 and a light chain variable region set forth in SEQ ID NO: 8. According to a specific embodiment, the Ab has a heavy chain variable region set forth in SEQ ID NO: 3 and a light chain variable region set forth in SEQ ID NO: 8.
[0099] Pharmaceutical composition
[0100] The present invention also provides a pharmaceutical composition comprising the above-mentioned antibody-drug conjugate and a pharmaceutically acceptable carrier.
[0101] According to a specific embodiment, the pharmaceutically acceptable carrier can be a pharmaceutically acceptable salt, such as an acid addition salt or a base addition salt (for example, as described in Berge, SM et al (1977) J.Pharma.Sci.66:1-19). The pharmaceutically acceptable carrier mentioned is acceptable to the subject at the dose or concentration used. Pharmaceutically acceptable carriers include, but are not limited to, buffers or salts, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, sodium acetate, citric acid, sodium citrate, citrate, Tris; carbohydrates, such as trehalose, polysorbate, sucrose, mannitol; surfactants such as polysorbate; preservatives such as hexamethonium chloride, benzalkonium chloride, benzethonium chloride; amino acids such as histidine, histidine hydrochloride, glycine, glutamine, asparagine, arginine or lysine, etc. Sterile pharmaceutical preparations can be obtained by methods commonly used in the art, for example, by filtration through a sterile filtration membrane. Those skilled in the art can select different pharmaceutically acceptable carriers for the pharmaceutical composition as needed to prepare different dosage forms, such as lyophilized dosage forms, injections, and other dosage forms. The prepared different pharmaceutical dosage forms can be formulated and administered to a subject by any suitable route of administration, including but not limited to intravenous, dermal, intramuscular, peritoneal, subcutaneous, nasal, oral, rectal, topical, inhalation, transdermal, and the like.
[0102] Reagent kit or medicine box
[0103] The present invention also provides a kit comprising the above-mentioned antibody-drug conjugate. The kit may further include a container, a buffer reagent, and controls such as a positive control and a negative control, as needed. Those skilled in the art can make appropriate selections as needed. Accordingly, the kit may also include instructions for use to facilitate operation and use by those skilled in the art. In some embodiments, the present invention also provides a drug kit comprising the above-mentioned antibody-drug conjugate.
[0104] Methods for preventing and / or treating disease
[0105] In addition, the present invention provides a method for preventing and / or treating a disease, comprising: administering an effective amount of the above-mentioned antibody-drug conjugate drug or the above-mentioned pharmaceutical composition to a subject in need.
[0106] The term "treat" refers to reducing the severity of disease symptoms, increasing the frequency and duration of symptom-free periods, or preventing a decrease in suffering caused by the disease. The effective amount of an antibody used to "prevent" a disease is generally lower than the effective amount used to treat the disease. An "effective amount" is an amount sufficient to achieve, or at least partially achieve, the desired effect. Following antibody drug conjugate treatment, the inhibition rate of tumor cells in the subject is greater than 10%, greater than 15%, greater than 20%, greater than 25%, greater than 30%, greater than 40%, greater than 45%, greater than 50%, greater than 55%, greater than 60%, greater than 65%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, or even greater than 90% or 95%, compared to a subject not treated with the antibody. The subject can be an animal or a human. For example, it can be a mammal, including cattle, sheep, mice, horses, etc.
[0107] The provided antibody-drug conjugates can be used to treat a variety of solid tumors and hematological malignancies in the human body, especially breast cancer, gastric cancer, colorectal cancer, urothelial carcinoma, ovarian cancer, uterine cancer, lung cancer (especially non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)), mesothelioma, liver cancer, thyroid cancer, melanoma, pancreatic cancer, bile duct cancer, esophageal cancer, head and neck cancer, prostate cancer, leukemia, synovial cancer, kidney cancer, connective tissue cancer, melanoma, esophageal cancer, colon cancer, rectal cancer, brain cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, von Hippel-Lindau ... renal cancer, connective tissue cancer, melanoma, esophageal cancer, colon cancer, rectal cancer, brain cancer, bone cancer, choriocarcinoma, gastrinoma Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bladder cancer, ureteral cancer, glioma, neuroblastoma, meningioma, spinal cord tumor, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, Paget's disease, cervical cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiple myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, peritoneal cancer, pleural cancer and blood cancer, etc.
[0108] The antibody-drug conjugates mentioned above can also be combined with other therapeutic approaches to treat diseases. These other therapeutic approaches may include chemotherapy or radiotherapy. By combining chemotherapy or radiotherapy with other therapeutic approaches in clinical practice, the therapeutic efficacy of the drug can be further enhanced, improving the treatment outcomes for patients.
[0109] The present invention also provides the use of an antibody-drug conjugate in preparing a kit for treating cancer. The provided antibodies or antigen-binding fragments can be used to prepare drugs for treating a variety of diseases. They can also be used to prepare kits for use as immunodiagnostic reagents.
[0110] The technical scheme of the present invention is described in detail below with reference to the embodiments. It should be noted that these embodiments are only used to facilitate the understanding of those skilled in the art and should not be regarded as limiting the scope of protection of the present invention. The embodiments of the present invention are described in detail below. The described embodiments are exemplary and are intended to be used to explain the present invention, but should not be understood as limiting the scope of the present invention.
[0111] HCT116 is a human colorectal cancer cell line. SK-HEP-1 is a human hepatoma cell line, and MC38 is a mouse colon cancer cell line. The HCT116-TT3 cell line mentioned is an HCT116 cell line stably expressing TT3, which was constructed by lentiviral transfection. Other cell lines, such as the SK-HEP-1 cell line stably expressing TT3 (SK-HEP-1-TT3) and the MC38 cell line stably expressing TT3 (MC38-TT3), were constructed by similar methods.
[0112] Please refer to the following methods for details:
[0113] Wild-type HCT116 cells were digested into single cells with 0.25% trypsin and plated at 1 × 10 5 / 500μL / well was inoculated in a 48-well plate, and 300μL of lentivirus LV-TT3-GFP and polybrene (commercially available from: Shanghai Yishen Biotechnology Co., Ltd., final concentration 8μg / mL) were added, placed in an incubator for culture and passage amplification. One week later, the infected cells were digested and inoculated into a 96-well plate at 2 cells / well, 100μL per well, and placed in an incubator for continued culture. After continuous culture for about 10 days to grow monoclonal cells, all cells were GFP-positive and there was only one cluster of cell clones. The wells were selected under a microscope and passaged and amplified. The expression of GFP and TT3 was detected by flow cytometry, and the optimal monoclonal clone was finally obtained according to the expression ratio and intensity of GFP and TT3, and a stable cell line expressing TT3 (HCT116-TT3) was obtained.
[0114] The antibody (numbered Ab-TT3, its heavy chain variable region is SEQ ID NO: 7, and its light chain variable region is SEQ ID NO: 8) was humanized. Specifically, based on the Ab-TT3 antibody sequence, a humanized sequence template was retrieved from the database. In order to maintain the conformation of the CDR region, three types of residues were focused on, including residues located at the VL and VH binding interface, residues close to the CDR region and embedded in the protein, and residues that directly interact with the CDR region. The interactions include: hydrophobic interactions, hydrogen bonds, and salt bridges. The 3D structure was analyzed for the importance of different amino acids, and if necessary, the key amino acids that affect the structure were reverse mutated to determine the corresponding humanized antibody.
[0115] Humanized antibodies were fused with human-derived constant region sequences and constructed into the PCDNA3.1 mammalian expression vector to form chimeric antibodies. The resulting antibodies were then expressed and purified using a mammalian cell system to obtain antibodies with a purity of at least 90%. The expressed antibodies were designated Ab-1hu, Ab-2hu, Ab-3hu, Ab-4hu, Ab-5hu, Ab-6hu, Ab-7hu, Ab-8hu, and Ab-9hu, respectively. Simultaneously, the Fc region of the Ab-3hu antibody was mutated to include the L234F / L235E / P331S mutations. The mutated antibody was designated Ab-3hu-mu. The activity of these antibodies was tested by ELISA using a TT3 antigen prepared by fusing the polypeptide represented by SEQ ID NO:24 with the GST protein sequence. The TT3 antigen was expressed and purified to detect the activity of the specific antibodies.
[0116] The activity of the prepared humanized antibodies was tested by ELISA. The experimental procedure was as follows: TT3 antigen was diluted to 0.5 μg / mL using coating buffer and 100 μL / well was added to a 96-well plate. The plate was incubated overnight at 4°C. The plate was washed with PBST, and then 200 μL of antibody blocking buffer was added to each well and blocked at 37°C for 2 hours. The plate was washed with PBST, and different antibodies (starting at 100 nM, serially diluted 1:6) were added at 100 μL / well and incubated at 37°C for 2 hours. The plate was washed with PBST, and HRP-conjugated goat anti-human / mouse IgG antibody was added at 100 μL / well and incubated at 37°C for 1 hour. The plate was washed with PBST, and TMB was added at 100 μL / well. The color was developed at 37°C for 10-20 minutes. The reaction was terminated by adding 50 μL of 2M sulfuric acid to each well. The OD value was read at a wavelength of 450 nm. The EC50 values of antibodies Ab-1hu, Ab-2hu, Ab-3hu, and Ab-TT3 were 0.0104 nM, 0.0105 nM, 0.0140 nM, and 0.0878 nM, respectively, as shown in FIG1 .
[0117] The activity of the humanized antibody prepared in Example 1 was tested by the FACS method. The experimental process was as follows: different cells (HCT116-TT3, SK-HEP-1-TT3, MC38-TT3) were plated, then washed with FACS buffer, centrifuged at 1200 rpm for 3-5 minutes, and different concentrations of diluted antibodies were added (starting at 100 nM, with a 1:5 gradient dilution), incubated at 4°C for 0.5 hours, and centrifuged at 1200 rpm for 3-5 minutes. After washing with FACS buffer, goat anti-human IgG secondary antibody (Abcam, ab98596) was diluted 1:250 and added to the plate at 100 uL / well. The cells were incubated at 4°C for 0.5 hours, centrifuged at 1200 rpm for 3-5 minutes, washed with FACS buffer, and then 50 uL of FACS buffer was added to resuspend the cells and analyzed by flow cytometry. Among them, the EC50 results of the FACs affinity activity of antibodies Ab-1hu, Ab-2hu, and Ab-3hu with HCT116-TT3 cells were 0.568nM, 0.958nM, and 0.692nM, respectively; the EC50 results of the FACs affinity activity with SK-HEP-1-TT3 cells were 0.546nM, 1.527nM, and 0.738nM, respectively; and the EC50 results of the FACs affinity activity with MC38-TT3 cells were 1.201nM, 2.327nM, and 0.588nM, respectively; as shown in Figure 1.
[0118] The same method was used to detect the antibody after Fc mutation (Ab-3hu-mu), and it was found that both before and after Fc mutation could bind to TT3 antigen and had biological activity, and the binding activity of the two was not much different.
[0119] These antibodies were used as examples to prepare antibody drug conjugates, and antibody drug conjugates with similar functions and activities were obtained. The following examples describe the preparation of antibody drug conjugates using antibody Ab-3hu-mu as an example.
[0120] Example 1 TT3-MMAE conjugate
[0121] Example 1 A TT3-MMAE conjugate was prepared by the following method, comprising:
[0122] (1) Antibody reduction
[0123] TT3-SH was obtained by reducing the disulfide bonds of an anti-TT3 antibody (Ab-3hu-mu) with tris(2-carboxyethyl)phosphine (TCEP). The procedure involved dissolving tris(2-carboxyethyl)phosphine (TCEP, 2 mg / mL) in a solution containing 0.025 M sodium borate, 0.025 M NaCl, and 5 mM EDTA (pH 7.5). Anti-TT3 antibody was then added at a molar ratio of TCEP to antibody of 5:1. The reaction was incubated at room temperature and 115 rpm for 2 hours to yield TT3-SH. After completion of the reaction, thiol content was analyzed using Ellman's reagent (DTNB).
[0124] DTNB is a widely used reagent for quantifying thiol groups. Its reaction product has an absorption peak at 412 nm, so DTNB can be used to determine the thiol content of TT3-SH. 90 μL of TT3-SH is incubated with 10 μL of DTNB (3.96 mg / mL) at room temperature for 15 minutes. The absorbance at 412 nm is measured using a UV-Vis spectrophotometer. The thiol content is calculated using a standard curve prepared by reacting GSH (0-1 mM) with DTNB.
[0125] The molar ratio of antibody to thiol was calculated to be 1:9.4.
[0126] (2) Preparation of Antibody Drug Conjugate TT3-MMAE
[0127] Freshly prepared VC-MMAE DMSO solution (10 mg / mL) was added to TT3-SH (TT3 antibody concentration was 2.5 mg / mL), and the molar ratio of TT3-SH to VC-MMAE was set to 1:10. After shaking at room temperature and 115 rpm for 2 h, free monoclonal antibody, TCEP and VC-MMAE were purified using a HIC column to obtain TT3-MMAE.
[0128] Example 2 Physical and Chemical Analysis of TT3-MMAE
[0129] Example 2 The antibody conjugate prepared in Example 1 was analyzed by SEC and SDS-PAGE. The absorbance of TT3-MMAE at 248 nm (MMAE absorbs at 248 nm) was measured using UV-Vis spectrophotometry, and the DAR value was calculated. The results are shown below:
[0130] (1) SDS-PAGE
[0131] The TT3-MMAE conjugate was analyzed by SDS-PAGE. During the purification process using HIC columns, the more hydrophobic the molecule, the later the peak elution time.
[0132] The results are shown in Figure 2. Numbers 1-9 represent samples collected at different peak elution times, with higher numbers indicating later sample collection times. The SDS-PAGE image shows that, with the exception of tube 1, all samples exhibit multiple bands. After disulfide bonds are reduced, non-covalent bonds between H and H and HL persist. However, the presence of SDS disrupts these non-covalent bonds, resulting in the observation of multiple bands such as H, L, and HL on SDS-PAGE. However, no small molecule fragments were detected on the SEC spectrum, indicating that the antibody is intact.
[0133] (2) SEC
[0134] The purity was determined by size exclusion chromatography (SEC, Waters ACQUITY Arc chromatograph). An XBridge Premier Protein SEC 250A column (7.8 mm x 300 mm, 2.5 μm) was used for analysis. The mobile phase was 100 mM phosphate buffer (pH 7.2-7.6) containing 200 mM arginine hydrochloride and 5% isopropanol, with a flow rate of 0.5 mL / min, a column temperature of 30°C, and a detection wavelength of 280 nm. The SEC results are shown in Figure 3. As can be seen from the SEC spectrum, the elution time of the TT3-MMAE conjugate is consistent with that of the anti-TT3 antibody, the purification process of the TT3-MMAE conjugate is good, the main peak accounts for a high proportion, and the main peak of the product has an obvious tailing phenomenon compared with the anti-TT3 antibody, indicating that the hydrophobic small molecule MMAE is successfully coupled to the anti-TT3 antibody.
[0135] (3) UV-Vis
[0136] The absorbance was measured at 248 nm using UV-visible light. The results are shown in Figure 4.
[0137] A standard curve was prepared based on the UV absorbance of MMAE (0.195-100 ug / mL) at 248 nm. Using an anti-TT3 antibody solution with the same antibody concentration as a baseline, the UV absorbance of the antibody-drug conjugate TT3-MMAE at 248 nm was 0.1746. Substituting this into the standard curve yielded a TT3-MMAE concentration of 14.7 ug / mL, and the calculated DAR was 8.38≈8.
[0138] Example 3 Functional Analysis
[0139] Example 3 studied the cell binding activity and antibody endocytosis of the prepared antibody drug conjugate TT3-MMAE.
[0140] The experiment is as follows:
[0141] (1) Cell binding activity
[0142] In order to investigate the binding of TT3-MMAE to cells overexpressing TT3, the binding of TT3-MMAE and anti-TT3 antibodies to HCT116-TT3 cells overexpressing TT3 and HCT116 cells not expressing TT3 was detected by flow cytometry.
[0143] First, HCT116-TT3 and HCT116 cells were digested with trypsin, resuspended and counted, and plated at 1E5 cells / well in a 96-well round-bottom plate. The cells were washed twice with FACs buffer (2% FBS + PBS) (1000 rpm, 5 min) and the supernatant was removed. Then, TT3-MMAE and anti-TT3 antibodies were serially diluted with FACs buffer (initial concentration was 100 nM, serially diluted 1:5, for a total of 8 dilution points), added to the 96-well round-bottom plate at 100 uL / well, and incubated at 4°C for 1 hour. After incubation, the cells were washed with FACs buffer. Anti-Human IgG (PE) secondary antibody was diluted 1:250 with FACs buffer and added to the 96-well round-bottom plate at 100 uL / well, and incubated at 4°C for 1 hour. Finally, the plate was washed twice with FACs buffer to remove unbound secondary antibody, and the cells were resuspended in 50 μL of FACs buffer and analyzed using flow cytometry. The results are shown in Figure 5 and Table 1 below.
[0144] Table 1 FACs binding activity
[0145] ND stands for not detected.
[0146] The experimental results showed that: 1) compared with the anti-TT3 antibody, the binding activity of the antibody-drug conjugate TT3-MMAE to HCT116-TT3 was not much different, indicating that the conjugation of MMAE to the anti-TT3 antibody did not affect the binding activity of the anti-TT3 antibody to the TT3 antigen;
[0147] 2) The antibody drug conjugate TT3-MMAE bound to HCT116-TT3 cells but not to HCT116 cells, indicating that the binding of the antibody drug conjugate TT3-MMAE to the TT3 antigen is specific.
[0148] (2) Antibody internalization
[0149] Flow cytometry was used to study the internalization of the antibody drug conjugate TT3-MMAE by HCT116-TT3 cells. First, HCT116-TT3 and HCT116 cells were digested with trypsin, resuspended and counted, and plated in a 96-well round-bottom plate at 1E5 cells / well. They were washed with FACs buffer (2% FBS + PBS) and centrifuged at 1000rpm for 5 minutes to remove the supernatant. Then, TT3-MMAE and TT3 were gradiently diluted with FACs buffer (initial concentration was 100nM, gradient dilution was performed 5-fold, and a total of 8 dilution points were added), added to a 96-well round-bottom plate at 100uL / well, and incubated at 4°C for 1h. After incubation, the cells were washed with FACs buffer and 100uL of culture medium was added to each well to resuspend the cells. The 0h sample was placed in a 4°C refrigerator for 2h, and the remaining samples were placed in a 37°C refrigerator for 2h. All samples were then centrifuged and washed with FACS buffer. Anti-Human IgG (Dylight 650) secondary antibody was diluted 1:250 in FACS buffer and added to the 96-well plate containing the samples at 100 μL / well. The plates were incubated at 4°C for 1 hour. Finally, the plates were washed twice with FACS buffer to remove unbound secondary antibody, and the cells were resuspended in FACS buffer and analyzed by flow cytometry. Endocytosis ratio = MFI (0 h) - MFI (2 h) / MFI (0 h).
[0150] As shown in Figure 6 and Table 2 below.
[0151] Table 2
[0152] The experimental results show that:
[0153] 1) Compared with the anti-TT3 mAb, the internalization degree of TT3-MMAE by HCT116-TT3 was not much different, indicating that MMAE conjugation did not affect the internalization of the antibody;
[0154] 2) TT3-MMAE and anti-TT3 antibodies are internalized through TT3 receptors.
[0155] (3) Cell killing
[0156] To investigate the cytotoxicity and targeting ability of the antibody-drug conjugate TT3-MMAE, the CCK8 assay was used to determine its inhibitory effect on the growth of TT3-positive HCT116-TT3 cells and TT3-negative HCT116 cells. HCT116-TT3 and HCT116 cells were plated at a density of 1E4 cells / well in a 96-well culture plate and incubated in a 37°C, 5% CO2 incubator for 24 hours. The culture medium was then replaced with 100 μL of culture medium containing varying concentrations of TT3-MMAE and TT3 monoclonal antibody. The plates were incubated in a 37°C, 5% CO2 incubator for 72 hours. Subsequently, 10 μL of CCK8 solution was added to each well and incubated for 2 hours. The UV absorbance at 450 nm was measured using a microplate reader. The cell viability was calculated by comparing the absorbance of each well at 450 nm (absorbance value of the culture medium was subtracted) with the absorbance of the PBS control group (absorbance value of the culture medium was subtracted), and the IC50 was calculated by Prism nonlinear regression (sigmoidal).
[0157] The results are shown in Figure 7. The experimental results show that:
[0158] 1) As shown in Figure 7A, after TT3-MMAE was co-incubated with HCT116-TT3 cells for 72 h, TT3-MMAE showed a significant killing effect in the cells with an IC50 of 1.02 nM, while TT3 monoclonal antibody had no killing effect.
[0159] 2) As shown in Figure 7B, after 72 hours of co-incubation of TT3-MMAE with HCT116 cells, neither the anti-TT3 antibody nor TT3-MMAE showed any killing effect, indicating that TT3-MMAE is specific for TT3-HCT116 cells. 3) The TT3 monoclonal antibody had no killing effect on either cell line, indicating that the specific killing effect is primarily due to the small molecule MMAE.
[0160] In the description of this specification, reference to the terms "one embodiment", "some embodiments", "implementation", "specific implementation", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention.
[0161] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.
Claims
1. Use of antibodies or antigen-binding fragments thereof targeting antigen epitope polypeptides in the preparation of antibody-drug conjugates; Wherein, in the natural state, the amino acid sequence of the mammalian cell membrane protein or secretory protein does not contain the amino acid sequence of the antigen epitope polypeptide; Compared with normal human cells, the antigen epitope polypeptide is differentially highly expressed on tumor cells / cancer cells, and the antibody or antigen binding fragment specifically binds to the antigen epitope polypeptide on the tumor cells / cancer cells and exhibits endocytosis with EC50≤100nM.
2. The use according to claim 1, characterized in that The amino acid sequence of the antigen epitope polypeptide is derived from the amino acid sequence of a protein existing in nature, or is an artificially synthesized amino acid sequence that does not exist in nature.
3. The use according to claim 2, characterized in that: The naturally occurring proteins include mammalian intracellular proteins, viral proteins, and other non-mammalian proteins.
4. The use according to claim 1, characterized in that The amino acid sequence of the antigen epitope polypeptide includes the amino acid sequence of the following tags: Myc tag, HA tag, Strep tag II, Strep tag I, Flag tag, HAT tag, S tag, S1 tag, protein C tag, tag-100 tag, E2 tag, TAP tag, HSV tag, KT3 tag, V5 tag, VSV-G tag, His tag or RFP tag.
5. The use according to claim 1, characterized in that: The amino acid sequence of the antigenic epitope polypeptide has one or more sequences derived from Strep tag I or Strep tag II; Optionally, the amino acid sequence of the antigenic epitope polypeptide has one or more repeated sequences derived from Strep tag I or Strep tag II; 6. The use according to claim 1, characterized in that: The antigen epitope polypeptide has a sequence as shown in SEQ ID NO:24 or SEQ ID NO:
25.
7. The use according to claim 1, characterized in that The extracellular antigen determining region is formed by the amino acid sequence of one or more antigen epitope polypeptides, and the extracellular antigen determining region is operably connected to the spacer part and the transmembrane part to form a marker polypeptide, and the marker polypeptide is expressed on tumor cells / cancer cells.
8. The use according to claim 7, characterized in that The spacer portion is derived from the hinge region of CD8α, the hinge region of IgG or the hinge region of IgD; wherein the transmembrane portion is derived from any type I transmembrane region sequence; Optionally, the transmembrane portion is derived from the transmembrane region of CD8, CD3ζ, CD4 or CD28.
9. The use according to claim 7, characterized in that: The amino acid sequence of the marker polypeptide is shown in SEQ ID NO: 18, 19, 20, 21 or 22.
10. The use according to claim 7, characterized in that The marker polypeptide is expressed on tumor cells / cancer cells through a recombinant virus, the genome of the recombinant virus has a marker polypeptide coding sequence, and the recombinant virus includes a selective replication-type recombinant oncolytic virus or a replication-deficient recombinant virus.
11. The use according to claim 10, characterized in that The recombinant oncolytic virus is derived from a genetically mutated virus with oncolytic effect and a wild-type virus with oncolytic effect; preferably, the recombinant oncolytic virus is derived from an adenovirus, poxvirus, herpes simplex virus, measles virus, Semliki Forest virus, vesicular stomatitis virus, poliovirus, retrovirus, reovirus, Seneca Valley virus, echovirus, coxsackievirus, Newcastle disease virus and Maraba virus with oncolytic effect.
12. The use according to claim 10, characterized in that The recombinant virus is configured for administration by intratumoral injection, intravenous administration, intraperitoneal injection or intracranial injection.
13. The use according to claim 10, characterized in that The coding sequence is DNA or RNA, and the RNA includes mRNA transcribed from DNA; Optionally, the DNA is formulated for administration by intratumoral injection, intravenous injection, intraperitoneal injection or intracranial injection; the mRNA is formulated for administration by intratumoral injection, intravenous injection, intraperitoneal injection or intracranial injection.
14. The use according to claim 1, characterized in that The antibody or antigen-binding fragment thereof is selected from a monoclonal antibody, a bispecific antibody, a multispecific antibody, a recombinant protein or a Fab fragment, a F(ab') fragment, a F(ab')2 fragment, a Fv fragment, a dAb, a Fd or a single-chain antibody.
15. The use according to claim 1, characterized in that The antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3, wherein: The amino acid sequences of HCDR1, HCDR2 and HCDR3 are CDR1, CDR2 and CDR3 of the heavy chain variable region as shown in SEQ ID NO: 7, The amino acid sequences of LCDR1, LCDR2 and LCDR3 are CDR1, CDR2 and CDR3 of the light chain variable region as shown in SEQ ID NO:
8. CDR3; Optionally, the CDR sequences of the antibody or antigen-binding fragment thereof are defined according to the IMGT definition scheme, as shown in SEQ ID NOs: 12 to 17.
16. The use according to claim 1, characterized in that The antibody or antigen-binding fragment thereof is selected from: has a heavy chain variable region shown in SEQ ID NO: 1 and a light chain variable region shown in SEQ ID NO: 4; or has a heavy chain variable region shown in SEQ ID NO: 1 and a light chain variable region shown in SEQ ID NO: 5; or Having a heavy chain variable region shown in SEQ ID NO: 1 and a light chain variable region shown in SEQ ID NO: 6; or has a heavy chain variable region shown in SEQ ID NO: 1 and a light chain variable region shown in SEQ ID NO: 8; or Having a heavy chain variable region shown in SEQ ID NO:2 and a light chain variable region shown in SEQ ID NO:4; or has a heavy chain variable region shown in SEQ ID NO: 2 and a light chain variable region shown in SEQ ID NO: 5; or has a heavy chain variable region shown in SEQ ID NO: 2 and a light chain variable region shown in SEQ ID NO: 6; or has a heavy chain variable region shown in SEQ ID NO: 2 and a light chain variable region shown in SEQ ID NO: 8; or Having a heavy chain variable region shown in SEQ ID NO:3 and a light chain variable region shown in SEQ ID NO:4; or has a heavy chain variable region shown in SEQ ID NO:3 and a light chain variable region shown in SEQ ID NO:5; or Having a heavy chain variable region shown in SEQ ID NO:3 and a light chain variable region shown in SEQ ID NO:6; or having a heavy chain variable region as shown in SEQ ID NO:3 and a light chain variable region as shown in SEQ ID NO:8; or Having a heavy chain variable region shown in SEQ ID NO:7 and a light chain variable region shown in SEQ ID NO:4; or has a heavy chain variable region shown in SEQ ID NO:7 and a light chain variable region shown in SEQ ID NO:5; or has a heavy chain variable region shown in SEQ ID NO:7 and a light chain variable region shown in SEQ ID NO:6; or It has a heavy chain variable region shown in SEQ ID NO:7 and a light chain variable region shown in SEQ ID NO:
8.
17. The use according to claim 1, characterized in that The antibody or antigen-binding fragment thereof further comprises a constant region of an immunoglobulin selected from IgG1, IgG2, IgG3, IgG4, or variants thereof.
18. Use of an antibody-drug conjugate in the preparation of a drug for treating cancer and / or tumors, characterized in that: The antibody-drug conjugate is an antibody or antigen-binding fragment thereof targeting an antigen epitope polypeptide coupled to one or more therapeutic agents; Wherein, in the natural state, the amino acid sequence of the mammalian cell membrane protein or secretory protein does not contain the amino acid sequence of the antigen epitope polypeptide; Compared with normal human cells, the antigen epitope polypeptide is differentially highly expressed on tumor cells / cancer cells, and the antibody or antigen binding fragment specifically binds to the antigen epitope polypeptide on the tumor cells / cancer cells and exhibits endocytosis with EC50≤100nM.
19. The use according to claim 18, characterized in that The antigen epitope polypeptide is the antigen epitope polypeptide according to any one of claims 1 to 17.
20. The use according to claim 18, characterized in that The therapeutic agent is selected from cytotoxic molecules, immunopotentiators and radioisotopes, Optionally, the cytotoxic molecule is selected from a tubulin inhibitor or a DNA damaging agent; Preferably, the tubulin inhibitor is selected from dolastatin or auristatin cytotoxic molecules, maytansine cytotoxic molecules; the DNA damaging agent is selected from calicheamicin, duocarmycin, anthramycin derivative PBD, camptothecins and camptothecin derivatives, SN-38, Dxd; The auristatin cytotoxic molecule is selected from MMAE or MMAF or their derivatives, and the maytansine cytotoxic molecule is selected from DM1, DM4 or their derivatives; Optionally, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3, wherein: The amino acid sequences of HCDR1, HCDR2 and HCDR3 are CDR1, CDR2 and CDR3 of the heavy chain variable region as shown in SEQ ID NO: 7, The amino acid sequences of LCDR1, LCDR2 and LCDR3 are CDR1, CDR2 and CDR3 of the light chain variable region as shown in SEQ ID NO:8; Optionally, the CDR sequences of the antibody or antigen-binding fragment thereof are defined according to the IMGT definition scheme, as shown in SEQ ID NOs: 12 to 17.
21. An antibody-drug conjugate targeting an antigen epitope polypeptide, characterized in that: An antibody or antigen-binding fragment thereof comprising a polypeptide targeting an antigenic epitope coupled to one or more therapeutic agents; Wherein, in the natural state, the amino acid sequence of the mammalian cell membrane protein or secretory protein does not contain the amino acid sequence of the antigen epitope polypeptide; Compared with normal human cells, the antigen epitope polypeptide is differentially highly expressed on tumor cells / cancer cells, and the antibody or antigen binding fragment specifically binds to the antigen epitope polypeptide on the tumor cells / cancer cells and exhibits endocytosis with EC50≤100nM.
22. The antibody-drug conjugate according to claim 21, characterized in that: The antigen epitope polypeptide is the antigen epitope polypeptide described in claims 1 to 17.
23. The antibody-drug conjugate according to claim 21, characterized in that: The therapeutic agent is selected from cytotoxic molecules, immunopotentiators and radioisotopes, Optionally, the cytotoxic molecule is selected from a tubulin inhibitor or a DNA damaging agent; Preferably, the tubulin inhibitor is selected from dolastatin or auristatin cytotoxic molecules, maytansine cytotoxic molecules; the DNA damaging agent is selected from calicheamicin, duocarmycin, anthramycin derivative PBD, camptothecins and camptothecin derivatives, SN-38, Dxd; The auristatin-type cytotoxic molecule is selected from MMAE or MMAF or derivatives thereof, and the maytansine-type cytotoxic molecule is selected from DM1, DM4 or derivatives thereof.
24. The antibody-drug conjugate according to claim 21, characterized in that: The general structural formula of the antibody-drug conjugate is Ab-(LU)n, wherein: The Ab represents an antibody or an antigen-binding fragment thereof targeting an antigen epitope polypeptide, The U is an active drug unit, The L is any linking group, and the L is covalently linked to the Ab and the U respectively; n is an integer selected from 1, 2, 3, 4, 5, 6, 7 or 8; One, two, three, four, five, six, seven, eight, nine or ten U's are connected to the Ab via one or more L's.
25. The antibody-drug conjugate according to claim 24, characterized in that: The L is covalently linked to an amino residue or a thiol residue on the Ab; Preferably, said L is covalently linked to a thiol residue on said Ab; More preferably, the L is covalently linked to the sulfhydryl residue formed after the interchain disulfide bonds on the Ab are opened.
26. The antibody-drug conjugate according to claim 24, characterized in that: The L includes a cleavable linker and a non-cleavable linker; The cleavable linker comprises 2 to 20 amino acid units, preferably, the amino acid units are selected from phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid, aspartic acid, valine-citrulline (Val-Cit), alanine-alanine-asparagine (Ala-Ala-Asn), glycine-glycine-lysine (Gly-Gly-lys), valine-lysine (Val-lys), valine-alanine (Val-Ala), valine-phenylalanine (Val-Phe) or glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly) or a combination thereof.
27. The antibody-drug conjugate according to claim 24, characterized in that: The L is selected from the following structures:
28. The antibody-drug conjugate according to claim 24, characterized in that: The U is selected from the following structures: Among them, in the general formula (I) R1 and R2 are each independently selected from H or C1-C6 alkyl; R3 is selected from C1-C8 alkyl; R4 and R5 are each independently selected from H, C1-C6 alkyl, aryl, or R4 and R5 form a C3-C8 membered ring; R6 is selected from C1-C8 alkyl; R7 is selected from C1-C8 alkyl; R8 is selected from H or C1-C8 alkyl; R9 is selected from H, C1-C8 alkyl, -OH, -COOH, -COO(C1-C6 alkyl), -CONH(C1-C6 alkyl), C5-C7 heterocycle; R 10 is selected from H, -OH, or a bond, when R 10 The OR formed when 10 =O; R 11 Selected from H, C1-C6 alkyl, or -OH; Preferably, R1 is independently selected from H or methyl, ethyl; Preferably, R3 is methyl, ethyl, isopropyl; Preferably, R4 and R5 are each independently H, methyl or ethyl; Preferably, R6 is H, methyl or ethyl; Preferably, R7 is methyl, ethyl, isopropyl, n-butyl, isobutyl; Preferably, R8 is H, methyl or ethyl; Preferably, R9 is methyl, -COOH, -CONH-CH3. Preferably, R 10 is H or -OH; Preferably, R 11 is H or -OH; Preferably, U is selected from the following structures:
29. The antibody-drug conjugate according to claim 24, characterized in that: The Ab comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3, wherein: The amino acid sequences of HCDR1, HCDR2 and HCDR3 are CDR1, CDR2 and CDR3 of the heavy chain variable region as shown in SEQ ID NO: 7, The amino acid sequences of LCDR1, LCDR2 and LCDR3 are CDR1, CDR2 and CDR3 of the light chain variable region as shown in SEQ ID NO:8; Optionally, the CDR sequences of the Ab are defined according to the IMGT definition scheme, as shown in SEQ ID NOs: 12 to 17.
30. The antibody-drug conjugate according to claim 24, characterized in that: The Ab is selected from: has a heavy chain variable region shown in SEQ ID NO: 1 and a light chain variable region shown in SEQ ID NO: 4; or has a heavy chain variable region shown in SEQ ID NO: 1 and a light chain variable region shown in SEQ ID NO: 5; or Having a heavy chain variable region shown in SEQ ID NO: 1 and a light chain variable region shown in SEQ ID NO: 6; or has a heavy chain variable region shown in SEQ ID NO: 1 and a light chain variable region shown in SEQ ID NO: 8; or Having a heavy chain variable region shown in SEQ ID NO:2 and a light chain variable region shown in SEQ ID NO:4; or has a heavy chain variable region shown in SEQ ID NO: 2 and a light chain variable region shown in SEQ ID NO: 5; or has a heavy chain variable region shown in SEQ ID NO: 2 and a light chain variable region shown in SEQ ID NO: 6; or has a heavy chain variable region shown in SEQ ID NO: 2 and a light chain variable region shown in SEQ ID NO: 8; or Having a heavy chain variable region shown in SEQ ID NO:3 and a light chain variable region shown in SEQ ID NO:4; or has a heavy chain variable region shown in SEQ ID NO:3 and a light chain variable region shown in SEQ ID NO:5; or Having a heavy chain variable region shown in SEQ ID NO:3 and a light chain variable region shown in SEQ ID NO:6; or having a heavy chain variable region as shown in SEQ ID NO:3 and a light chain variable region as shown in SEQ ID NO:8; or Having a heavy chain variable region shown in SEQ ID NO:7 and a light chain variable region shown in SEQ ID NO:4; or has a heavy chain variable region shown in SEQ ID NO:7 and a light chain variable region shown in SEQ ID NO:5; or has a heavy chain variable region shown in SEQ ID NO:7 and a light chain variable region shown in SEQ ID NO:6; or It has a heavy chain variable region shown in SEQ ID NO:7 and a light chain variable region shown in SEQ ID NO:
8.
31. A pharmaceutical composition, characterized in that The invention comprises the antibody-drug conjugate according to any one of claims 21 to 30, and a pharmaceutically acceptable carrier.
32. A kit, characterized in that The invention comprises the antibody-drug conjugate according to any one of claims 21 to 30.
33. A method for preventing and / or treating a disease, characterized in that: include: Administering an effective amount of the antibody-drug conjugate according to any one of claims 21 to 30, or the pharmaceutical composition according to claim 31 to a subject in need thereof; Optionally, the disease is a tumor and / or cancer.
34. The method according to claim 33, characterized in that The tumors and / or cancers include: breast cancer, head and neck tumors, synovial cancer, kidney cancer, connective tissue cancer, melanoma, lung cancer, esophageal cancer, colon cancer, rectal cancer, brain cancer, liver cancer, bone cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, anal cancer, bile duct cancer, bladder cancer, ureteral cancer, glioma, neuroblastoma, meningioma, spinal cord tumor, osteochondroma, chondrosarcoma, Ewing's sarcoma, carcinoma of unknown primary site, carcinoid, fibrosarcoma, Paget's disease, cervical cancer, gallbladder cancer, eye cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, squamous cell carcinoma of the skin, mesothelioma, multiple myeloma, ovarian cancer, pancreatic endocrine tumor, glucagonoma, pancreatic cancer, penile cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymic cancer, trophoblastic carcinoma, hydatidiform mole, endometrial cancer, vaginal cancer, vulvar cancer, mycosis fungoides, insulinoma, heart cancer, meningeal cancer, peritoneal cancer, pleural cancer, and at least one of blood cancer.
35. Use of the antibody-drug conjugate according to any one of claims 21 to 30 in the preparation of a drug or a kit.
36. Use of antibodies or antigen-binding fragments thereof targeting antigen epitope polypeptides in the preparation of antibody-drug conjugates; Wherein, in the natural state, the amino acid sequence of the mammalian cell membrane protein or secretory protein does not contain the amino acid sequence of the antigen epitope polypeptide; Compared with normal human cells, the antigen epitope polypeptide is differentially and highly expressed on tumor cells / cancer cells, and the antibody or antigen binding fragment specifically binds to the antigen epitope polypeptide on the tumor cells / cancer cells; The amino acid sequence of the antigenic epitope polypeptide has one or more sequences derived from Strep tag I or Strep tag II.
37. An antibody-drug conjugate targeting an antigen epitope polypeptide, characterized in that: An antibody or antigen-binding fragment thereof comprising a polypeptide targeting an antigenic epitope coupled to one or more therapeutic agents; Wherein, in the natural state, the amino acid sequence of the mammalian cell membrane protein or secretory protein does not contain the amino acid sequence of the antigen epitope polypeptide; Compared with normal human cells, the antigen epitope polypeptide is differentially and highly expressed on tumor cells / cancer cells, and the antibody or antigen binding fragment specifically binds to the antigen epitope polypeptide on the tumor cells / cancer cells; The amino acid sequence of the antigenic epitope polypeptide has one or more sequences derived from Strep tag I or Strep tag II.
Citation Information
Patent Citations
Preparation and use method of novel broad-spectrum therapeutic tumour vaccine
CN103933558A
Therapeutic agent containing nucleic acid and CAR modified immune cells and application thereof
CN110856724A
Trispecific binding molecules against tumor-associated antigents and use thereof
US20200362054A1
Strep-tag specific chimeric receptors and uses thereof
US20210023132A1
High-affinity monoclonal Anti-strep-tag antibody
WO2015067768A1
